REGULATORY

Chuikyo OKs New Drug Pricing Rules for 2020 Reform

January 23, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council, an all-important reimbursement policy panel better known as Chuikyo, gave its official stamp of approval to new NHI drug pricing rules from April 2020 at its general assembly and drug pricing subcommittee meetings on…

To read the full story

Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019

REGULATORY

Celltrion’s Eylea Biosimilar Nears Approval, but Listing Outlook Clouded
February 27, 2026
Japan Panel to Review Joenja, Dojolvi for Approval at March 5 Session
February 27, 2026
Executives Urge Stronger CDMO, CRO Base at Drug Discovery WG Meeting
February 27, 2026
Japan to Closely Monitor US “MFN” Policy: PM Takaichi
February 27, 2026
Japan to Update Adult Pneumococcal Fact Sheet Ahead of Capvaxive NIP Review
February 27, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…